【据APASL2014年报道】题:利用前S2抗原预测治疗反应(作者Seon Joo Ahn等)HBsAg的消失通常预示着乙型肝炎的临床治愈,来自韩国亚洲大学医学院的研究人员建议,在核苷和核苷酸类药物(NUCs)治疗的过程中,应用前S2抗原水平预测HBsAg和HBeAg的转阴。该研究纳入30位接受NUCs治疗的慢性乙型肝炎患者。在治疗过程中,半数患者HBsAg降低到检测线以下。起初30例患者中有22例HBeAg阳性,在治疗的过程中,有14例患者HBeAg转阴,说明病毒复制不再活跃。所有患者的前S2抗原滴度下降。然而,Seon Joo Ahn博士指出:HBsAg持续存在的患者的前S2抗原水平显 [APASL2014 report] Title: Prediction of response to treatment with pre-S2 antigen (by Seon Joo Ahn, et al) The disappearance of HBsAg usually indicates a clinical cure for hepatitis B. Researchers from the Asian University School of Medicine in South Korea suggested that nucleoside and Nucleotide drugs (NUCs) in the process of treatment, the application of pre-S2 antigen levels predicted HBsAg and HBeAg negative conversion. The study enrolled 30 patients with chronic hepatitis B treated with NUCs. During treatment, half of HBsAg in patients decreased to below the detection line. At first, 22 of 30 patients were HBeAg positive. During the course of treatment, 14 patients had HBeAg negative, indicating that viral replication was no longer active. The titer of pre-S2 antigen decreased in all patients. However, Dr Seon Joo Ahn pointed out that pre-S2 antigen levels in patients with HBsAg persistence were significantly